No benefit with early invasive strategy in patients with NSTE-ACS and elevated troponin T
This article has no abstract so we have provided the first paragraph of the full text.
Trials comparing an early invasive treatment strategy with more-conservative strategies in patients with non-ST-segment-elevation acute coronary syndrome (NSTE-ACS) have shown divergent results with regard to survival and cardiovascular events. At 1 year, the ICTUS trial showed no benefit of an early invasive strategy over a selective invasive strategy in patients with NSTE-ACS and elevated cardiac troponin T levels. Longer term data from the same trial have confirmed these findings.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
